nature
Title:
Correction of a pathogenic gene mutation in human embryos
Journal:
Nature 548, 413–419
Author(s):
Ma H1, Marti-Gutierrez N1, Park SW2, Wu J3, Lee Y1, Suzuki K3, Koski A1, Ji D1, Hayama T1, Ahmed R1, Darby H1, Van Dyken C1, Li Y1, Kang E1, Park AR2, Kim D4, Kim ST2, Gong J5,6,7,8, Gu Y5,6,7, Xu X5,6,7, Battaglia D1,9, Krieg SA9, Lee DM9, Wu DH9, Wolf DP1, Heitner SB10, Belmonte JCI3, Amato P1,9, Kim JS2,4, Kaul S10, Mitalipov S1,10
Author(s) affiliation:
1 Center for Embryonic Cell and Gene Therapy, Oregon Health and Science University, 3303 Southwest, Bond Avenue, Portland, Oregon 97239, USA.
2Center for Genome Engineering, Institute for Basic Science, 70, Yuseong-daero 1689-gil, Yuseong-gu, Daejeon, 34047, Republic of Korea.
3 Gene Expression Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, California 92037, USA.
4 Department of Chemistry, Seoul National University, 599 Gwanak-ro, Gwanak-gu, Seoul, 151-747, Republic of Korea.
5 BGI-Shenzhen, Build 11, Beishan Industrial Zone, Yantian District, Shenzhen, 518083, China.
6 China National GeneBank, BGI-Shenzhen, Jinsha Road, Dapeng District, Shenzhen, 518210, China.
7 BGI-Qingdao, 2877 Tuanjie Road, Sino-German Ecopark, Qingdao, 266000, China.
8 Shenzhen Engineering Laboratory for Innovative Molecular Diagnostics, BGI-Shenzhen, Build 11, Beishan Industrial Zone, Yantian District, Shenzhen, 518083, China.
9Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Oregon Health and Science University, 3303 Southwest, Bond Avenue, Portland, Oregon 97239, USA.
10Knight Cardiovascular Institute, Oregon Health and Science University, 3181 Southwest, Sam Jackson Park Road, Portland, Oregon 97239, USA.
 

 

Short description:
Genome editing has potential for the targeted correction of germline mutations. Here we describe the correction of the heterozygous MYBPC3 mutation in human preimplantation embryos with precise CRISPR–Cas9-based targeting accuracy and high homology-directed repair efficiency by activating an endogenous, germline-specific DNA repair response. Induced double-strand breaks (DSBs) at the mutant paternal allele were predominantly repaired using the homologous wild-type maternal gene instead of a synthetic DNA template. By modulating the cell cycle stage at which the DSB was induced, we were able to avoid mosaicism in cleaving embryos and achieve a high yield of homozygous embryos carrying the wild-type MYBPC3 gene without evidence of off-target mutations. The efficiency, accuracy and safety of the approach presented suggest that it has potential to be used for the correction of heritable mutations in human embryos by complementing preimplantation genetic diagnosis. However, much remains to be considered before clinical applications, including the reproducibility of the technique with other heterozygous mutations.
Link to the journal
 

 

Abstract taken from PubMed

Abstract:
Genome editing has potential for the targeted correction of germline mutations. Here we describe the correction of the heterozygous MYBPC3 mutation in human preimplantation embryos with precise CRISPR–Cas9-based targeting accuracy and high homology-directed repair efficiency by activating an endogenous, germline-specific DNA repair response. Induced double-strand breaks (DSBs) at the mutant paternal allele were predominantly repaired using the homologous wild-type maternal gene instead of a synthetic DNA template. By modulating the cell cycle stage at which the DSB was induced, we were able to avoid mosaicism in cleaving embryos and achieve a high yield of homozygous embryos carrying the wild-type MYBPC3 gene without evidence of off-target mutations. The efficiency, accuracy and safety of the approach presented suggest that it has potential to be used for the correction of heritable mutations in human embryos by complementing preimplantation genetic diagnosis. However, much remains to be considered before clinical applications, including the reproducibility of the technique with other heterozygous mutations.
Link to the paper on PubMed
 




IVF-Worldwide.com endeavors to ensure that the information in this article is accurate,reliable and up to date. However, the information is provided "as is" without warranty of any kind. IVF-Worldwide does not accept any responsibility or liability for the accuracy,content, completeness, legality, or reliability of the information contained in this article.
IVF-Worldwide.com is not responsible for the content of other websites linked to or referenced from this website. The website does not endorse the information, content,presentation or accuracy of such other websites and does not make any warranty,express or implied, regarding them.